Literature DB >> 21225475

High-throughput mutation profiling in intraductal papillary mucinous neoplasm (IPMN).

Nir Lubezky1, Menahem Ben-Haim, Sylvia Marmor, Eli Brazowsky, Gideon Rechavi, Joseph M Klausner, Yoram Cohen.   

Abstract

BACKGROUND: Specific mutations leading to the development of various histological grades of intraductal papillary mucinous neoplasm (IPMN) have been partially characterized.
METHODS: Analysis of 323 oncogenic mutations in 22 tumor-related genes was conducted, using a chip-based matrix-assisted laser desorption time-of-flight mass spectrometer of DNA extracted from microdissected cells of low-grade (n = 14), borderline (n = 6), and invasive IPMN (n = 7). Additional assays were performed on the DNA extracted from dyplastic cells found in the background of the adenocarcinoma.
RESULTS: We identified 9 K-ras mutations (low grade, 2/14; borderline, 1/6; invasive, 6/7), 3 p53 mutations (low grade, 1/14; invasive 2/7), and 2 PIK3CA mutations (low grade, 1/14; invasive, 1/7). K-ras, p53, and PIK3CA mutations present in the invasive cancer were absent in the adjacent precursor cells in 50% of the cases. In one patient, K-ras mutation was present in the precursor lesion and absent in the adjacent invasive lesion.
CONCLUSIONS: Of the 22 screened tumor-related genes, only K-ras, p53, and PIK3CA mutations were found in IPMN. K-ras mutations are more prevalent in invasive than premalignant IPMN. The variable coexistence of mutations in the invasive cancer and in the adjacent precursor cells may point to the heterogeneous nature of this tumor.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21225475     DOI: 10.1007/s11605-010-1411-8

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  32 in total

Review 1.  International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas.

Authors:  Masao Tanaka; Suresh Chari; Volkan Adsay; Carlos Fernandez-del Castillo; Massimo Falconi; Michio Shimizu; Koji Yamaguchi; Kenji Yamao; Seiki Matsuno
Journal:  Pancreatology       Date:  2006       Impact factor: 3.996

2.  PIK3CA mutations in advanced ovarian carcinomas.

Authors:  Yun Wang; Aslaug Helland; Ruth Holm; Gunnar B Kristensen; Anne-Lise Børresen-Dale
Journal:  Hum Mutat       Date:  2005-03       Impact factor: 4.878

3.  Purification of DNA from formaldehyde fixed and paraffin embedded human tissue.

Authors:  S E Goelz; S R Hamilton; B Vogelstein
Journal:  Biochem Biophys Res Commun       Date:  1985-07-16       Impact factor: 3.575

4.  Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas.

Authors:  Toru Furukawa; Rumi Fujisaki; Yoshitaro Yoshida; Naomi Kanai; Makoto Sunamura; Tadayoshi Abe; Kazunori Takeda; Seiki Matsuno; Akira Horii
Journal:  Mod Pathol       Date:  2005-08       Impact factor: 7.842

5.  BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreas.

Authors:  Frank Schönleben; Wanglong Qiu; Karl C Bruckman; Nancy T Ciau; Xiaojun Li; Margaret H Lauerman; Harold Frucht; John A Chabot; John D Allendorf; Helen E Remotti; Gloria H Su
Journal:  Cancer Lett       Date:  2006-11-09       Impact factor: 8.679

6.  Does "clonal progression" relate to the development of intraductal papillary mucinous tumors of the pancreas?

Authors:  Keita Wada; Tadahiro Takada; Hideki Yasuda; Hodaka Amano; Masahiro Yoshida; Maki Sugimoto; Hiroshi Irie
Journal:  J Gastrointest Surg       Date:  2004 Mar-Apr       Impact factor: 3.452

7.  Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients.

Authors:  F Sessa; E Solcia; C Capella; M Bonato; A Scarpa; G Zamboni; N S Pellegata; G N Ranzani; F Rickaert; G Klöppel
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

8.  Intraductal papillary mucinous neoplasms of the pancreas: an updated experience.

Authors:  Taylor A Sohn; Charles J Yeo; John L Cameron; Ralph H Hruban; Noriyoshi Fukushima; Kurtis A Campbell; Keith D Lillemoe
Journal:  Ann Surg       Date:  2004-06       Impact factor: 12.969

9.  High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas.

Authors:  K Grünewald; J Lyons; A Fröhlich; H Feichtinger; R A Weger; G Schwab; J W Janssen; C R Bartram
Journal:  Int J Cancer       Date:  1989-06-15       Impact factor: 7.396

10.  Mutations of PIK3CA in gastric adenocarcinoma.

Authors:  Vivian Sze Wing Li; Chi Wai Wong; Tsun Leung Chan; Agnes Sze Wah Chan; Wei Zhao; Kent-Man Chu; Samuel So; Xin Chen; Siu Tsan Yuen; Suet Yi Leung
Journal:  BMC Cancer       Date:  2005-03-23       Impact factor: 4.430

View more
  14 in total

Review 1.  Pathological and molecular evaluation of pancreatic neoplasms.

Authors:  Arvind Rishi; Michael Goggins; Laura D Wood; Ralph H Hruban
Journal:  Semin Oncol       Date:  2014-12-09       Impact factor: 4.929

Review 2.  Intraductal Papillary Mucinous Neoplasms of the Pancreas: Current Understanding and Future Directions for Stratification of Malignancy Risk.

Authors:  Annabelle L Fonseca; Kimberly Kirkwood; Michael P Kim; Anirban Maitra; Eugene J Koay
Journal:  Pancreas       Date:  2018-03       Impact factor: 3.327

3.  Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice.

Authors:  Janel L Kopp; Claire L Dubois; David F Schaeffer; Atefeh Samani; Farnaz Taghizadeh; Robert W Cowan; Andrew D Rhim; Bangyan L Stiles; Mark Valasek; Maike Sander
Journal:  Gastroenterology       Date:  2017-12-19       Impact factor: 22.682

4.  Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer.

Authors:  Sujuan Yang; Sara P Y Che; Paul Kurywchak; Jena L Tavormina; Liv B Gansmo; Pedro Correa de Sampaio; Michael Tachezy; Maximilian Bockhorn; Florian Gebauer; Amanda R Haltom; Sonia A Melo; Valerie S LeBleu; Raghu Kalluri
Journal:  Cancer Biol Ther       Date:  2017-01-25       Impact factor: 4.742

Review 5.  Pancreatic cancer genomes: toward molecular subtyping and novel approaches to diagnosis and therapy.

Authors:  Laura D Wood
Journal:  Mol Diagn Ther       Date:  2013-10       Impact factor: 4.074

6.  Loss of PTEN expression is associated with poor prognosis in patients with intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Dario Garcia-Carracedo; Andrew T Turk; Stuart A Fine; Nathan Akhavan; Benjamin C Tweel; Ramon Parsons; John A Chabot; John D Allendorf; Jeanine M Genkinger; Helen E Remotti; Gloria H Su
Journal:  Clin Cancer Res       Date:  2013-10-16       Impact factor: 12.531

Review 7.  Pathology and molecular genetics of pancreatic neoplasms.

Authors:  Laura D Wood; Ralph H Hruban
Journal:  Cancer J       Date:  2012 Nov-Dec       Impact factor: 3.360

Review 8.  Genomic landscapes of pancreatic neoplasia.

Authors:  Laura D Wood; Ralph H Hruban
Journal:  J Pathol Transl Med       Date:  2015-01-15

9.  Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas.

Authors:  Eliana Amato; Marco Dal Molin; Andrea Mafficini; Jun Yu; Giuseppe Malleo; Borislav Rusev; Matteo Fassan; Davide Antonello; Yoshihiko Sadakari; Paola Castelli; Giuseppe Zamboni; Anirban Maitra; Roberto Salvia; Ralph H Hruban; Claudio Bassi; Paola Capelli; Rita T Lawlor; Michael Goggins; Aldo Scarpa
Journal:  J Pathol       Date:  2014-07       Impact factor: 7.996

10.  Role of emerging molecular markers in pancreatic cyst fluid.

Authors:  Mohammad Al-Haddad
Journal:  Endosc Ultrasound       Date:  2015 Oct-Dec       Impact factor: 5.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.